CSIMarket
 
Aveo Pharmaceuticals Inc   (AVEO)
Other Ticker:  
 
 
Price: $15.0000 $0.00 0.000%
Day's High: $15 Week Perf: 0.2 %
Day's Low: $ 14.99 30 Day Perf: 0.67 %
Volume (M): 248 52 Wk High: $ 0.00
Volume (M$): $ 3,717 52 Wk Avg: $0.00
Open: $14.99 52 Wk Low: $0.00



 Market Capitalization (Millions $) 519
 Shares Outstanding (Millions) 35
 Employees -
 Revenues (TTM) (Millions $) 95
 Net Income (TTM) (Millions $) -29
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0

Aveo Pharmaceuticals Inc
Aveo Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing targeted cancer therapies. The company primarily focuses on developing medicines that inhibit the growth and spread of tumors and improve patients' outcomes. Their primary product candidate is tivozanib, a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, which is being developed as a treatment for advanced renal cell carcinoma and other types of cancer. Aveo Pharmaceuticals Inc is committed to advancing their pipeline of innovative therapies to address unmet medical needs.


   Company Address: 30 Winter Street Boston 2108 MA
   Company Phone Number: 400-0101   Stock Exchange / Ticker: AVEO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

In-depth Analysis of Tivozanib?s Efficacy in Treating Advanced Renal Cell Carcinoma: Long-term Results from the Phase III TIVO-3 Trial?

Published Tue, Feb 6 2024 1:10 PM UTC

AVEO Oncology recently announced the publication of significant results related to the long-term survival of patients with relapsed or refractory advanced Renal Cell Carcinoma (RCC) who have been treated with Tivozanib. The data, derived from a pivotal Phase III TIVO-3 Trial, provides valuable insights into the potential benefits of this treatment in enhancing the longevity ...

Clinical Study

AVEO Oncology Initiates Pivotal Clinical Trial to Evaluate Ficlatuzumab and ERBITUX Combination Therapy for HPV-Negative Head and Neck Cancer Patients

Published Tue, Jan 16 2024 12:30 PM UTC

AVEO Oncology, a subsidiary of LG Chem, has recently commenced enrollment for the FIERCE-HN trial, a highly anticipated phase 3 clinical trial. This global study aims to evaluate the efficacy and safety of AVEO's investigational antibody, Ficlatuzumab, in combination with ERBITUX (cetuximab), an anti-EGFR antibody. The trial specifically focuses on patients diagnosed with hu...






 

Aveo Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com